Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023

2023-08-17
上市批准临床3期
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat
seizure disorders
, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event will feature presentations from Marinus management and Key Opinion Leaders to discuss the Company’s clinical pipeline progress, strategic initiatives and business outlook. In-person attendance is open to invited research analysts and institutional investors. All others are invited to watch the live video webcast. Live questions will be taken by in-person guests, and virtual participants may submit questions through the webcast platform. To register for the video webcast, please visit the Investor Relations section of the Company's website at . A replay of the webcast will be archived on the Investor Relations section of the Company's website following the event. About Marinus Pharmaceuticals Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for
seizure disorders
. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of
seizures
associated with
CDKL5 deficiency disorder
CDKL5
deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare
seizure disorders
, including in Phase 3 trials in
tuberous sclerosis complex
and
refractory status epilepticus
. Ganaxolone is a neuroactive steroid GABAA receptor modulator
GABAA receptor
modulator that acts on a well-characterized target in the brain known to have anti-
seizure
effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit .
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
癫痫,癫痫发作,CDKL5缺乏症
[+2]
靶点
CDKL5,GABAA receptor
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。